Evidence map›Paper›PMID 31237643›Full record

ArticleJAMA2019

Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Surya P Bhatt, Pallavi P Balte, Joseph E Schwartz, Patricia A Cassano, David Couper, David R Jacobs, Ravi Kalhan, George T O'Connor, Sachin Yende, Jason L Sanders and 5 more

Abstract read
In one paragraph

Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. New spirometry recommendations from the Brazilian Thoracic Association - 2024 update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Surya P BhattDivision of Pulmonary, Allergy, and Critical Care Medicine and the UAB Lung Health Center, University of Alabama at Birmingham.
Pallavi P BalteDivision of General Medicine, Columbia University Medical Center, New York, New York.
Joseph E SchwartzDivision of General Medicine, Columbia University Medical Center, New York, New York.
Patricia A CassanoDivision of Nutritional Sciences, Weill Cornell Medical College, Ithaca, New York.
David CouperGillings School of Global Public Health, University of North Carolina, Chapel Hill.
David R JacobsDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Ravi KalhanDivision of Pulmonary and Critical Care Medicine, Northwestern University, Chicago, Illinois.
George T O'ConnorDivision of Pulmonary, Allergy, Sleep, and Critical Care, Boston University, Boston, Massachusetts.
Sachin YendeDepartment of Critical Care Medicine, University of Pittsburgh and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Jason L SandersDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Jason G UmansMedStar Health Research Institute, Hyattsville, Maryland.
Mark T DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine and the UAB Lung Health Center, University of Alabama at Birmingham.
Paulo H ChavesBenjamin Leon Center for Geriatric Research and Education, Florida International University, Miami.
Wendy B WhiteUndergraduate Training and Education Center, Tougaloo College, Tougaloo, Mississippi.
Elizabeth C OelsnerDivision of General Medicine, Columbia University Medical Center, New York, New York.

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
SUBCLINICAL CARDIOVASCULAR DISEASE COORDINATING CENTERN01HC95159 · NHLBI · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 2007 to 2014
$19.6M
Pulmonary microvascular perfusion in the Multi-Ethnic Study of AtherosclerosisR01HL077612 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2004 to 2026
$18.8M
Transitions from Impaired Respiratory Health to Lung DiseaseR01HL122477 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI RAVI KALHAN · 2014 to 2026
$17.3M
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary Disease (COPD)R01HL093081 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI R Graham BARR · 2008 to 2026
$17.2M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC95160 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL · 2007 to 2015
$7.7M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC95164 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LIU, KIANG · 2007 to 2015
$7.0M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC95161 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SHEA, STEVEN · 2007 to 2014
$6.4M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC95165 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BURKE, GREGORY L · 2007 to 2014
$6.3M
Chronic obstructive pulmonary disease in non-smokersR01HL130506 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERBSTMAN, JULIE BETH, SMITH, BENJAMIN M. · 2016 to 2025
$6.3M
NCATS NIH HHS UL1 TR001409NHLBI NIH HHS K23 HL130627NHLBI NIH HHS K23 HL133438NHLBI NIH HHS K24 HL140108NHLBI NIH HHS N01HC95159NHLBI NIH HHS N01HC95160NHLBI NIH HHS N01HC95161NHLBI NIH HHS N01HC95162NHLBI NIH HHS N01HC95163NHLBI NIH HHS N01HC95164NHLBI NIH HHS N01HC95165NHLBI NIH HHS N01HC95166NHLBI NIH HHS N01HC95167NHLBI NIH HHS N01HC95168NHLBI NIH HHS N01HC95169NHLBI NIH HHS R01 HL077612NHLBI NIH HHS R01 HL093081NHLBI NIH HHS R01 HL122477NHLBI NIH HHS R01 HL130506NHLBI NIH HHS R21 HL129924NHLBI NIH HHS RC1 HL100543NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS R01 AG023629NIA NIH HHS R01 AG028050NINR NIH HHS R01 NR012459
6 · The paper itself

Abstract

Importance: According to numerous current guidelines, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1:FVC) of less than 0.70, yet this fixed threshold is based on expert opinion and remains controversial. Objective: To determine the discriminative accuracy of various FEV1:FVC fixed thresholds for predicting COPD-related hospitalization and mortality. Design, Setting, and Participants: The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts Study harmonized and pooled data from 4 US general population-based cohorts (Atherosclerosis Risk in Communities Study; Cardiovascular Health Study; Health, Aging, and Body Composition Study; and Multi-Ethnic Study of Atherosclerosis). Participants aged 45 to 102 years were enrolled from 1987 to 2000 and received follow-up longitudinally through 2016. Exposures: Presence of airflow obstruction, which was defined by a baseline FEV1:FVC less than a range of fixed thresholds (0.75 to 0.65) or less than the lower limit of normal as defined by Global Lung Initiative reference equations (LLN). Main Outcomes and Measures: The primary outcome was a composite of COPD hospitalization and COPD-related mortality, defined by adjudication or administrative criteria. The optimal fixed FEV1:FVC threshold was defined by the best discrimination for these COPD-related events as indexed using the Harrell C statistic from unadjusted Cox proportional hazards models. Differences in C statistics were compared with respect to less than 0.70 and less than LLN thresholds using a nonparametric approach. Results: Among 24 207 adults in the pooled cohort (mean [SD] age at enrollment, 63 [10.5] years; 12 990 [54%] women; 16 794 [69%] non-Hispanic white; 15 181 [63%] ever smokers), complete follow-up was available for 11 077 (77%) at 15 years. During a median follow-up of 15 years, 3925 participants experienced COPD-related events over 340 757 person-years of follow-up (incidence density rate, 11.5 per 1000 person-years), including 3563 COPD-related hospitalizations and 447 COPD-related deaths. With respect to discrimination of COPD-related events, the optimal fixed threshold (0.71; C statistic for optimal fixed threshold, 0.696) was not significantly different from the 0.70 threshold (difference, 0.001 [95% CI, -0.002 to 0.004]) but was more accurate than the LLN threshold (difference, 0.034 [95% CI, 0.028 to 0.041]). The 0.70 threshold provided optimal discrimination in the subgroup analysis of ever smokers and in adjusted models. Conclusions and Relevance: Defining airflow obstruction as FEV1:FVC less than 0.70 provided discrimination of COPD-related hospitalization and mortality that was not significantly different or was more accurate than other fixed thresholds and the LLN. These results support the use of FEV1:FVC less than 0.70 to identify individuals at risk of clinically significant COPD.

Indexed as

Forced Expiratory VolumeVital CapacityAgedAged, 80 and overCohort StudiesFemaleHospitalizationHumansMaleMiddle AgedPrognosisProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRisk Assessment

Identifiers

PMID31237643
PMCPMC6593636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.